Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis

[1]  A. Hottinger,et al.  Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors , 2023, Cell reports. Medicine.

[2]  M. Ladanyi,et al.  Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  S. Li,et al.  The spatial transcriptomic landscape of non-small cell lung cancer brain metastasis , 2022, Nature Communications.

[4]  Jon Griffin,et al.  Gene of the month: NKX3.1 , 2022, Journal of Clinical Pathology.

[5]  Weiwei Dong,et al.  Homozygous deletion of the HLA-B gene as an acquired-resistance mechanism to nivolumab in a patient with lung adenocarcinoma: a case report , 2021, Annals of translational medicine.

[6]  David R. Jones,et al.  Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients , 2021, Cell.

[7]  J. Chiang,et al.  CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition , 2021, Hereditary cancer in clinical practice.

[8]  D. Pe’er,et al.  Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis , 2020, Science.

[9]  Nicholas D. Camarda,et al.  Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma , 2020, Nature Genetics.

[10]  F. Garrido,et al.  Cancer immune escape: MHC expression in primary tumours versus metastases , 2019, Immunology.

[11]  Qian Zhao,et al.  Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer. , 2019, Lung cancer.

[12]  B. Taylor,et al.  Genome doubling shapes the evolution and prognosis of advanced cancers , 2018, Nature Genetics.

[13]  J. Reis-Filho,et al.  Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases , 2018, Oncotarget.

[14]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[15]  Eudocia Q Lee,et al.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study , 2017, Neuro-oncology.

[16]  A. Gazdar,et al.  Genome‐wide copy number variation pattern analysis and a classification signature for non‐small cell lung cancer , 2017, Genes, chromosomes & cancer.

[17]  Yi-long Wu,et al.  Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[19]  Salvatore Piscuoglio,et al.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma , 2015, Nature Communications.

[20]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[21]  Frederick S. Vizeacoumar,et al.  RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs , 2013, PloS one.

[22]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[23]  OUP accepted manuscript , 2022, The Oncologist.

[24]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.